Idiopathic pulmonary fibrosis (IPF) remains a disease with poor survival. The pathogenesis
is complex and encompasses multiple molecular pathways. The first-generation antifibrotics …

For decades, topical corticosteroids have been the mainstay of treatment for mild-to-
moderate inflammatory skin diseases, even though only short-term use is approved for these …

Introduction There is an unmet need for new treatments for idiopathic pulmonary fibrosis
(IPF). The oral preferential phosphodiesterase 4B inhibitor, BI 1015550, prevented a decline …

Abstract Phosphodiesterase-4B (PDE4B), a sub-type of PDE4, is highly expressed in the
brain and associated with schizophrenia, neuroinflammation, and cognition. A selective …

Introduction The Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2)
infection involves pulmonary inflammation that can progress to acute respiratory distress …

Systemic sclerosis (SSc), or scleroderma, is a rare, complex, systemic autoimmune disease
of unknown aetiology, characterized by high morbidity and mortality often resulting from …

Aim: This study aimed to develop biomimetic nanoparticles (NPs) of roflumilast (ROF) for
attenuating myocardial ischemia/reperfusion (MI/R) injury. Materials & methods: We …

特发性肺纤维化(IPF) 是一种进行性, 不可逆和典型的慢性纤维化肺病, 近年来, 对IPF
的病理生理学认识, 临床诊断和治疗有了显著进展. 但至目前为止, 仍然没有治愈IPF 的方法 …

Background Interstitial lung disease (ILD) has exhibited limited overall treatment
advancements, with scant exploration into circulating protein biomarkers causally linked to …

Idiopathic pulmonary fibrosis (IPF) is a progressive, irreversible and typical chronic fibrotic
lung disease. In recent years, significant progress has been made in the pathophysiology …